**Doc No.05a (i, ii)**

**Selectt Offer schedules CM\_PHR\_20\_5610\_01 ,02 ,03 ,04 & 05**

**Invitation to offer for NHS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®),**

**Offer reference number: CM/PHR/20/5600**

**CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months**

**CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.**

**CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework:  1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.**

**CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework:  1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.**

**CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework:  1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.**

Document No. 05a (i, ii,) within the ITO is not actually a document, but a link to an application called SELECTT.